CASR and pulmonary arterial hypertension: Pharmacological blockade and targeted deletion of CaSR has been shown to inhibit the CaSR-mediated increase in [Ca2+]cyt and attenuates the development of experimental-induced pulmonary hypertension in animal models of the disease.